

Supplementary Table 1. Other socio-demographic characteristics and disease features of the 45 patients.

Categorical variables	n (%)
Disease localization	
– Pulmonary only	37 (82.2)
– Pulmonary + Extrapulmonary	7 (15.6)
– Extrapulmonary only	1 (2.2)
Diabetes	6 (13.3)
Any other chronic immunocompromising disease	5 (11.1)
Alcohol abuse	9 (20.0)
Intravenous drug use	18 (40.0)
Active smoking	33 (73.3)
Homeless	38 (84.4)
Previously imprisoned	8 (17.8)
Any psychiatric disorder	6 (13.3)
Previous TB treatment on admission	
– None	11 (24.4)
– First-line drugs only	7 (15.6)
– Any second-line drug	27 (60.0)

Supplementary Table 2. Detailed severity and seriousness profile of the adverse events experienced by the 45 patients.

Categorical variables	n (%)		
N of patients experiencing:	Total AE	Severe AE	Serious AE
- Gastrointestinal AE	34 (75.6)	4 (8.9)	1 (2.2)
- Liver enzyme elevation	17 (37.8)	3 (6.7)	0
- Oto-vestibular AE	25 (55.6)	5 (11.1)	0
- Peripheral neuropathy	18 (40.0)	13 (28.9)	1 (2.2)
- Optic neuropathy	5 (11.1)	1 (2.2)	0
- Tendinopathy	1 (2.2)	0	0
- Arthralgia	6 (13.3)	0	0
- Anaemia	5 (11.1)	0	0
- Neutropenia	1 (2.2)	0	0
- Thrombocytopenia	6 (13.3)	0	0
- Renal failure	5 (11.1)	2 (4.4)	0
- Hypothyroidism	3 (6.7)	0	0
- Any psychiatric disorder	10 (22.2)	2 (4.4)	0
- Allergy / skin rash	8 (17.8)	0	0
- QT prolongation	13 (28.9)	5 (11.1)	0
- Others	10 (22.2)	10 (22.2)	6
o Pancreatitis	1 (2.2)	1 (2.2)	0
o Sepsis, bacterial	1 (2.2)	1 (2.2)	1 (2.2)
o Sepsis, candida	1 (2.2)	1 (2.2)	1 (2.2)
o Pulmonary embolism	1 (2.2)	1 (2.2)	0
o Coronary dissection during coronarography	1 (2.2)	1 (2.2)	1 (2.2)
o Drug-associated pneumonia (not confirmed)	1 (2.2)	1 (2.2)	0
o Stroke	1 (2.2)	1 (2.2)	0
o Deep vein thrombosis	1 (2.2)	1 (2.2)	0
o Death	3 (6.7)	3 (6.7)	3 (6.7)

AE = adverse events

Supplementary Table 3. Comparison of baseline characteristics of patients receiving standard (≤ 190 days) or prolonged (>190 days) bedaquiline (Bdq) treatment.

Categorical variables, n (%)	Standard Bdq treatment (N=12)	Prolonged Bdq treatment (N=33)	p-value
Sex, male	6 (50.0)	30 (90.9)	0.006
XDR-TB patient	4 (33.3)	20 (60.6)	0.176
HIV infection	0	2 (6.0)	1.000
HCV infection	2 (16.7)	19 (57.6)	0.020
Bilateral pulmonary involvement	6 (63.6) (N=11)	29 (87.9)	0.092
Cavities on chest radiography	9 (81.8) (N=11)	30 (90.9)	0.586
Culture positive on sputum at treatment start	9 (75.0)	32 (97)	0.048
Smear positive on sputum at treatment start	11 (91.7)	31 (93.9)	0.616
Any previous tuberculosis treatment	3 (25.0)	31 (94)	<0.001
Previous treatment with second-line drugs	1 (8.3)	26 (78.8)	<0.001
Continuous variables, median (interquartile range)			
Age at admission (years)	41 (27 – 56)	38 (30 – 40)	0.209
Number of molecules to which the isolate was resistant	6 (5 – 13)	9 (8 – 11)	0.171
Body mass index	20.1 (17.3 – 22.9)	19.4 (17.9 – 21.8)	0.626
Albumin	32.8 (30.8 – 37.4)	32.5 (26.9 – 36.6)	0.472

XDR-TB = extensively drug-resistant tuberculosis.